Perspective Therapeutics price target raised to $2.20 from $1.50 at JonesResearch

JonesResearch raised the firm’s price target on Perspective Therapeutics to $2.20 from $1.50 and keeps a Buy rating on the shares following the Q1 report. The firm says the company’s “data rich” second half of 2024 coincides with an expanding pipeline. In the context of strong momentum in the radiopharmaceutical space fueled by commercial and clinical success as well as high levels of takeover activity, Prspective’s stock remains undervalued, the analyst tells investors in a research note.